What Clairyon does

Clairyon (formerly Healcisio Inc.) is a private healthcare AI company founded in 2022 and headquartered in La Jolla, California, that builds a multimodal AI-powered clinical intelligence platform for hospital systems and clinical teams. Its product stack centers on three proprietary deep learning models: COMPOSER for early sepsis prediction 4–48 hours before clinical suspicion (with claim of 75–85% false alarm reduction versus legacy systems), KIDMATCH for differentiating Kawasaki disease from MIS-C in pediatric patients (90%+ accuracy), and WUPERR for cross-hospital generalization trained on over 104,000 patient records across four healthcare systems. The platform is extended with GenAI-driven automated quality measure abstraction (e.g., CMS SEP-1), an AI agent for sepsis care compliance, and an outpatient personal health companion leveraging LLMs and consumer wearables for post-discharge surveillance.

The company serves enterprise healthcare provider customers—primarily academic hospital systems—through a direct enterprise field sales motion with clinical pilot validations and integration via HL7 FHIR. UC San Diego Health is the anchor reference customer (62+ monitored care units, 200,000+ patients impacted, 17% relative sepsis mortality reduction in a peer-reviewed study), with Rady Children's Hospital as the principal pediatric validation partner and SEQSTER as a recent data integration partner for real-time longitudinal records. It is HIPAA and SOC 2 Type II compliant and is pursuing FDA clearance for KIDMATCH.

Clairyon's business model is subscription-based SaaS deployed through hospital system contracts, though pricing is not publicly disclosed; the website relies on 'Request Demo' CTAs indicating quote-based enterprise agreements. The company is currently funded primarily by non-dilutive NIH grants (~ $2.37M disclosed across NIH STTR and RADx Tech awards) and a Nucleate San Diego prize, and operates with a small team of approximately 10–15 people spanning engineering, clinical, and program coordination roles.

Name

Clairyon

Legal name

Clairyon

Website

https://clairyon.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Clairyon is a La Jolla–based healthcare AI startup that builds a multimodal clinical intelligence platform—anchored by its COMPOSER sepsis prediction model and KIDMATCH pediatric diagnostic tool—deployed primarily at academic hospital systems via enterprise SaaS contracts.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software (Healthcare AI)

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)

akta.pro secondary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

Keywords

• Clinical decision support
• Sepsis early prediction
• Hospital quality reporting
• Multimodal healthcare AI
• Patient deterioration monitoring

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. AI-Powered Clinical Intelligence Platform: SaaS-based clinical intelligence solutions deployed in hospital systems. Revenue likely generated through software licensing and subscription model based on care units monitored or patient volume.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Clairyon sells a multimodal AI-powered clinical intelligence platform for hospital systems, featuring real-time deep learning models that monitor patient data (vital signs, labs, medications, EHR notes) to predict adverse events such as sepsis 4-48 hours before clinical suspicion. Its products include COMPOSER for sepsis early warning, KIDMATCH for pediatric MIS-C vs. Kawasaki Disease differentiation, and WUPERR for multi-hospital generalization, with GenAI-powered automation of CMS quality measure abstraction (SEP-1).

Product overview

Clairyon offers a unified multimodal AI-powered clinical intelligence platform with two core products: COMPOSER for real-time sepsis prediction and KIDMATCH for pediatric inflammatory condition differentiation. The platform is enhanced by WUPERR for multi-hospital generalization, GenAI-powered quality reporting automation, real-time clinical decision support, and outpatient monitoring via wearables. All solutions share a unified infrastructure for early adverse event detection, quality improvement, and patient outcome optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• COMPOSER Conformal Multidimension Prediction of Sepsis Risk (COMPOSER) is a deep learning model that continuously monitors over 150 patient variables (vital signs, lab results, medications, comorbidities, and EHR context) to predict sepsis 4-48 hours before clinical suspicion, with a 75-85% reduction in false alarms versus legacy systems. It is deployed for hospital emergency departments, ICUs, and wards.
• KIDMATCH A deep learning algorithm that uses patient age, the five classic signs of clinical Kawasaki Disease, and 17 laboratory measurements to differentiate Multisystem Inflammatory Syndrome in Children (MIS-C) from Kawasaki Disease (KD) with 90%+ accuracy. It is intended for pediatric hospitals and pediatric emergency departments.
• WUPERR Weight Uncertainty Propagation and Episodic Representation Replay (WUPERR) is a sepsis prediction model trained on EHR data of over 104,000 patients across four healthcare systems. It uses elastic weight consolidation and episodic representation replay to generalize across hospital settings without requiring patient-level data sharing.
• AI Agent for Sepsis Care Compliance An AI-driven Clinical Abstraction Agent that automates SEP-1 sepsis quality measure abstraction and delivers near-real-time compliance feedback to care teams, achieving 92% agreement with expert human reviewers and a 13 percentage-point improvement in SEP-1 compliance (from 70.1% to 82.9%). It is intended for hospital quality and sepsis program teams.

Quantifiable outcome

• 17% relative reduction in sepsis mortality (1.9 percentage point absolute decrease from 11.39% to 9.5%)
• +6 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• SEQSTERcoreTechnology or Integration · 11 June 2026Strategic partnership to bring real-time patient data into sepsis care. SEQSTER's longitudinal health data platform integrates with Clairyon's predictive AI to power early warning and post-discharge surveillance capabilities. Combines SEQSTER's patient data orchestration with Clairyon's COMPOSER model for earlier sepsis detection and faster intervention.
• Xpertech SolutionsminorOthersListed as an industry partner on the company team page.
• AstuteminorOthersListed as an industry partner on the company team page.
• UC San Diego HealthcoreStrategic or Co-development PartnerPrimary clinical partner and deployment site. UC San Diego Health is the anchor institution where COMPOSER was developed and first deployed. Multiple joint research studies published in peer-reviewed journals. Company co-founders and advisors affiliated with UCSD School of Medicine.
• Rady Children's HospitalcoreStrategic or Co-development PartnerClinical partner for KIDMATCH algorithm validation. Data from 1,517 patients used to develop MIS-C vs Kawasaki disease differentiation algorithm. Algorithm externally validated on cohorts from multiple children's hospitals.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CLEW Medical: CLEW provides CLEWICU, a predictive analytics platform for ICU patients that uses AI to predict hemodynamic instability and deterioration hours in advance, directly competing with Clairyon's real-time clinical surveillance and deterioration prediction capabilities.
• Inflammatix: Inflammatix develops host-response based diagnostics and AI for acute infection and sepsis triage, targeting similar hospital decision support use cases around early sepsis identification and risk stratification that Clairyon addresses with COMPOSER.
• PeraHealth: PeraHealth's Rothman Index uses a proprietary algorithm to detect patient deterioration from EHR data in real time — a directly comparable patient surveillance and clinical deterioration early-warning approach to Clairyon's COMPOSER platform.
• Etiometry: Etiometry's T3 Platform aggregates ICU data streams and applies AI to support clinical decision-making for critically ill patients, including pediatric populations — overlapping with both Clairyon's COMPOSER adult monitoring and KIDMATCH pediatric diagnostic applications.
• Prenosis: Prenosis develops the FDA-authorized Sepsis ImmunoScore, an AI-enabled diagnostic for early sepsis risk stratification that integrates EHR data with clinical biomarkers — directly competing with Clairyon's COMPOSER for sepsis early warning deployments in hospital systems.

Broad incumbents

• Wolters Kluwer: Wolters Kluwer's Sentri7 and POC Advisor early warning systems provide real-time sepsis surveillance and clinical decision support across thousands of hospitals, representing a broad incumbent competitor to Clairyon's enterprise hospital sepsis platform.
• Epic Systems: Epic embeds sepsis screening modules (e.g., Best Practice Advisories) directly within its dominant EHR platform used by most US academic medical centers — including UCSD — creating a major incumbent threat that Clairyon must displace or integrate alongside.
• GE Healthcare: GE Healthcare offers ICU patient monitoring (Edwards partnership), analytics, and hospital-wide clinical surveillance solutions that compete with Clairyon's real-time patient monitoring and deterioration prediction capabilities across health system buyers.
• Philips: Philips provides IntelliVue patient monitoring and a portfolio of hospital clinical informatics and analytics solutions (including connected care/ICU offerings) that overlap with Clairyon's enterprise hospital surveillance and clinical intelligence positioning.

Emerging players

• MedAware: MedAware applies AI-driven clinical decision support for medication safety and patient-specific risk identification in hospital workflows, representing an emerging adjacent player targeting the same hospital AI clinical decision support category as Clairyon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/clairyon

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clairyon